Lon S. Schneider MD

Geriatric Psychiatry

Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California Director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center

Join to View Full Profile

1520 San Pablo StSte 1652Los Angeles, CA 90033
Phone+1 323-442-6000
Fax+1 323-442-6001

Education & Training

University of Southern California School of MedicineMS, Applied Biometry and Epidemiology, 1995
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Psychiatry, 1978 - 1983
Drexel University College of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1979 - 2027
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Geriatric Psychiatry

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

CATIE-Alzheimer's Disease Trial Start of enrollment: 2001 Mar 01
Completed
Not Applicable
Citalopram for Agitation in Alzheimer's Disease Start of enrollment: 2009 Jul 01
Completed
Phase 3
Phytoserms for Menopause Symptoms and Age-Associated Memory Decline Start of enrollment: 2012 Jul 01
Completed
Not Applicable
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD Start of enrollment: 2014 Aug 01
Completed
Phase 1
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study Start of enrollment: 2019 Oct 01
Active, not recruiting
Phase 1
Development of Novel Measures for Alzheimer's Disease Prevention Trials Start of enrollment: 2019 Feb 25
ACTIVE_NOT_RECRUITING
NA
Join now to see all

Publications & Presentations

PubMed

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
Tarek K Rajji, Sheriza N Baksh, David M Shade, Zahinoor Ismail, Amer M Burhan
Nature Medicine. 2025-03-25
Reflections on The Lancet's Commission on dementia prevention, intervention, and care - Authors' reply.
Gill Livingston, Sergi G Costafreda, Mika Kivimäki, Naaheed Mukadam, Lon S Schneider
Lancet. 2025-02-22
B vitamins and the 2024 Lancet Commission on dementia.
Gill Livingston, Sergi G Costafreda, Mika Kivimaki, Naaheed Mukadam, Geir Selbaek
Lancet. 2025-02-22

Press Mentions

Two Patients Navigate the New Alzheimer's DrugsMarch 3rd, 2025
Alzheimer's Data WithdrawnNovember 11th, 2024
If Alzheimer's Drug Ads Had More Data, Here's What Might HappenAugust 30th, 2024
Join now to see all

Grant Support

Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.INSTITUTE FOR MOLECULAR MEDICINE2022–2027
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.INSTITUTE FOR MOLECULAR MEDICINE2022–2027
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.INSTITUTE FOR MOLECULAR MEDICINE2022–2027
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.INSTITUTE FOR MOLECULAR MEDICINE2022–2027
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical TrialUNIVERSITY OF ARIZONA2019–2026
(-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trialUNIVERSITY OF SOUTHERN CALIFORNIA2019–2025
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention TrialsNEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC2018–2025